Bovine Herpesvirus Tegument Protein VP22 Enhances Thymidine Kinase/Ganciclovir Suicide Gene Therapy for Neuroblastomas Compared to Herpes Simplex Virus VP22

Journal of Virology

Volumn 78, Issue 8, 2004, Pages 4224-4233

  Qiu, Zhaohua ^a   Harms, Jerome S ^a   Zhu, Jun ^a   Splitter, Gary A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b AHABS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; PROTEIN; PROTEIN P53; PROTEIN VP22; STRUCTURAL PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; BOVINE HERPES VIRUS; CELL DEATH; CYTOTOXICITY; EFFECTOR CELL; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; INTEGUMENT; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SUICIDE GENE; VIRUS CAPSID;

ANIMALS; ARTIFICIAL GENE FUSION; CATTLE; CELL LINE, TUMOR; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 4, EQUID; HUMANS; MICE; NEUROBLASTOMA; THYMIDINE KINASE; TRANSFECTION; VIRAL STRUCTURAL PROTEINS;

EID: 1842484010     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.8.4224-4233.2004     Document Type: Article

References (37)

1. Bennett, R. P., B. Dalby, and P. M. Guy. 2002. Protein delivery using VP22. Nat. Biotechnol. 20:20.
2. Bi, W. L., L. M. Parysek, R. Warnick, and P. J. Stambrook. 1993. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4:725-731.
3. Brewis, N., A. Phelan, J. Webb, J. Drew, G. Elliott, and P. O'Hare. 2000. Evaluation of VP22 spread in tissue culture. J. Virol. 74:1051-1056.
4. Dargan, D. 1986. The structure and assembly of herpes viruses, p. 359-437. In J. R. Harris and R. W. Horne (ed.), Viral structure. Academic Press, New York, N.Y.
5. Dilber, M. S., M. R. Abedi, B. Christensson, B. Bjorkstrand, G. M. Kidder, C. C. Naus, G. Gahrton, and C. I. Smith. 1997. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57:1523-1528.
6. Dilber, M. S., A. Phelan, A. Aints, A. J. Mohamed, G. Elliott, C. I. Smith, and P. O'Hare. 1999. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 6:12-21.
7. Elliott, G., and P. O'Hare. 2000. Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division. J. Virol. 74:2131-2141.
8. Elliott, G., and P. O'Hare. 1997. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-233.
9. Elliott, G., and P. O'Hare. 1999. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 6:149-151.
10. Falnes, P. O., J. Wesche, and S. Olsnes. 2001. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 40:4349-4358.
11. Fang, B., B. Xu, P. Koch, and J. A. Roth. 1998. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther. 5:1420-1424.
12. Freeman, S. M., K. A. Whartenby, J. L. Freeman, C. N. Abboud, and A. J. Marrogi. 1996. In situ use of suicide genes for cancer therapy. Semin. Oncol. 23:31-45.
13. Greene, L. A., W. Shain, A. Chalazonitis, X. Breakfield, J. Minna, H. G. Coon, and M. Nirenberg. 1975. Neuronal properties of hybrid neuroblastoma x sympathetic ganglion cells. Proc. Natl. Acad. Sci. USA 72:4923-4927.
14. Harms, J. S., X. Ren, S. C. Oliveira, and G. A. Splitter. 2000. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J. Virol. 74:3301-3312.
15. Ishii-Morita, H., R. Agbaria, C. A. Mullen, H. Hirano, D. A. Koeplin, Z. Ram, E. H. Oldfield, D. G. Johns, and R. M. Blaese. 1997. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4:244-251.
16. Klatzmann, D., P. Cherin, G. Bensimon, O. Boyer, A. Coutellier, F. Charlotte, C. Boccaccio, J. L. Salzmann, S. Herson, et al. 1998. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Hum. Gene Ther. 9:2585-2594.
17. Liu, C. S., B. Kong, H. H. Xia, K. A. Ellem, and M. Q. Wei. 2001. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J. Gene Med. 3:145-152.
18. Loubiere, L., M. Tiraby, C. Cazaux, E. Brisson, M. Grisoni, J. Zhao-Emonet, G. Tiraby, and D. Klatzmann. 1999. The equine herpesvirus 4 thymidine kinase is a better suicide gene than the human herpesvirus 1 thymidine kinase. Gene Ther. 6:1638-1642.
19. Martin, A., P. O'Hare, J. McLauchlan, and G. Elliott. 2002. Herpes simplex virus tegument protein VP22 contains overlapping domains for cytoplasmic localization, microtubule interaction, and chromatin binding. J. Virol. 76:4961-4970.
20. Normand, N., H. van Leeuwen, and P. O'Hare. 2001. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276:15042-15050.
21. Phelan, A., G. Elliott, and P. O'Hare. 1998. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16:440-443.
22. Ren, X., J. S. Harms, and G. A. Splitter. 2001. Bovine herpesvirus 1 tegument protein VP22 interacts with histones, and the carboxyl terminus of VP22 is required for nuclear localization. J. Virol. 75:8251-8258.
23. Rosolen, A., E. Frascella, C. di Francesco, A. Todesco, M. Petrone, M. Mehtali, F. Zacchello, L. Zanesco, and M. Scarpa. 1998. In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther. 5:113-120.
24. Roy, I., L. Holle, W. Song, E. Holle, T. Wagner, and X. Yu. 2002. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res. 22:3185-3189.
25. Ruch, R. J. 1994. The role of gap junctional intercellular communication in neoplasia. Ann. Clin. Lab. Sci. 24:216-231.
26. Sciortino, M. T., B. Taddeo, A. P. Poon, A. Mastino, and B. Roizman. 2002. Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc. Natl. Acad. Sci. USA 99:8318-8323.
27. Shinoura, N., L. Chen, M. A. Wani, Y. G. Kim, J. J. Larson, R. E. Warnick, M. Simon, A. G. Menon, W. L. Bi, and P. J. Stambrook. 1996. Protein and messenger RNA expression of connexin 43 in astrocytomas: implications in brain tumor gene therapy. J. Neurosurg. 84:839-845.
28. Spear, P. G., and B. Roizman. 1972. Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion. J. Virol. 9:143-159.
29. St Clair, M. H., C. U. Lambe, and P. A. Furman. 1987. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob. Agents Chemother. 31:844-849.
30. Steven, A. C., and P. G. Spear. 1997. Herpesvirus capsid assembly and envelopment, p. 312-351. In W. Chiu, R. M. Burnett, and R. L. Carcea (ed.), Structural biology of viruses. Oxford University Press, New York, N. Y.
31. Vrionis, F. D., J. K. Wu, P. Qi, M. Waltzman, V. Cherington, and D. C. Spray. 1997. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 4:577-585.
32. Wei, M. X., P. Bougnoux, B. Sacre-Salem, M. B. Peyrat, C. Lhuillery, J. L. Salzmann, and D. Klatzmann. 1998. Suicide gene therapy of chemically induced mammary tumor in rat: efficacy and distant bystander effect. Cancer Res. 58:3529-3532.
33. Wills, K. N., I. A. Atencio, J. B. Avanzini, S. Neuteboom, A. Phelan, J. Philopena, S. Sutjipto, M. T. Vaillancourt, S. F. Wen, R. O. Ralston, and D. E. Johnson. 2001. Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus. J. Virol. 75:8733-8741.
34. Wybranietz, W. A., C. D. Gross, A. Phelan, P. O'Hare, M. Spiegel, F. Graepler, M. Bitzer, P. Stahler, M. Gregor, and U. M. Lauer. 2001. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther. 8:1654-1664.
35. Zavaglia, D., M. C. Favrot, B. Eymin, C. Tenaud, and J. L. Coll. 2003. Intercellular trafficking and enhanced in vivo antitumour activity of a non-vitally delivered P27-VP22 fusion protein. Gene Ther. 10:314-325.
36. Zender, L., R. Kock, M. Eckhard, B. Frericks, T. Gosling, T. Gebhardt, S. Drobek, M. Galanski, F. Kuhnel, M. Manns, and S. Kubicka. 2002. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 123:608-618.
37. Zender, L., F. Kuhnel, R. Kock, M. Manns, and S. Kubicka. 2002. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther. 9:489-496.